Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma

• Published in: Clinical cancer research Vol. 26; no. 22; pp. 6028 - 6038
• Main Authors: Sherbenou, Daniel W, Su, Yang, Behrens, Christopher R, Aftab, Blake T, Perez de Acha, Olivia, Murnane, Megan, Bearrows, Shelby C, Hann, Byron C, Wolf, Jeffery L, Martin, Thomas G, Liu, Bin
• Format: Journal Article
• Language: English
• Published: United States 15.11.2020
• Subjects: ADP-ribosyl Cyclase 1 - antagonists & inhibitors; ADP-ribosyl Cyclase 1 - immunology; Adult; Aged; Animals; Antibodies, Anti-Idiotypic - immunology; Antibodies, Anti-Idiotypic - pharmacology; Antibodies, Monoclonal - pharmacology; Cell Line, Tumor; Cell Proliferation - drug effects; Female; Flow Cytometry; Heterografts; Humans; Immunoconjugates - immunology; Immunoconjugates - pharmacology; Intercellular Adhesion Molecule-1 - genetics; Intercellular Adhesion Molecule-1 - immunology; Male; Mice; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - immunology; Multiple Myeloma - pathology

New therapies have changed the outlook for patients with multiple myeloma, but novel agents are needed for patients who are refractory or relapsed on currently approved drug classes. Novel targets other than CD38 and BCMA are needed for new immunotherapy development, as resistance to daratumumab and...